Molecular detection of primary bladder cancer by microsatellite analysis

Science

Volumn 271, Issue 5249, 1996, Pages 659-662

  Mao, Li ^a   Schoenberg, Mark P ^b   Scicchitano, Marshall ^a   Erozan, Yener S ^b   Merlo, Adrian ^a   Schwab, Donna ^a   Sidransky, David ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICROSATELLITE DNA; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CLINICAL ARTICLE; CYSTOSCOPY; FEMALE; GENOME; HETEROZYGOSITY; HUMAN; MALE; PRIORITY JOURNAL; URINALYSIS; URINE CYTOLOGY; URINE SEDIMENT;

EID: 0030034080     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.271.5249.659     Document Type: Article

References (34)

1. C C. Boring, T. S. Squires, T. Tong, Cancer J. Clin. 45, 8 (1995).
2. G. N. Papanicolaou and V. F. Marshall, Science 101, 519 (1945).
3. G. M. Farrow, D. C. Utz, C C Rife, Cancer Res 36, 2495 (1976); W. M. Murphy, M. S. Soloway, A. F. Jukkola, W. N Crabtree, K S Ford, Cancer (Philadelphia) 53, 1555 (1984); C. T. Sarnacki et al. J Urol. 106, 761 (1971); M. N El-Bolkainy, ibid. 124, 20 (1980).
4. G. M. Farrow, D. C. Utz, C C Rife, Cancer Res 36, 2495 (1976); W. M. Murphy, M. S. Soloway, A. F. Jukkola, W. N Crabtree, K S Ford, Cancer (Philadelphia) 53, 1555 (1984); C. T. Sarnacki et al. J Urol. 106, 761 (1971); M. N El-Bolkainy, ibid. 124, 20 (1980).
5. G. M. Farrow, D. C. Utz, C C Rife, Cancer Res 36, 2495 (1976); W. M. Murphy, M. S. Soloway, A. F. Jukkola, W. N Crabtree, K S Ford, Cancer (Philadelphia) 53, 1555 (1984); C. T. Sarnacki et al. J Urol. 106, 761 (1971); M. N El-Bolkainy, ibid. 124, 20 (1980).
6. G. M. Farrow, D. C. Utz, C C Rife, Cancer Res 36, 2495 (1976); W. M. Murphy, M. S. Soloway, A. F. Jukkola, W. N Crabtree, K S Ford, Cancer (Philadelphia) 53, 1555 (1984); C. T. Sarnacki et al. J Urol. 106, 761 (1971); M. N El-Bolkainy, ibid. 124, 20 (1980).
7. S. C Hopkins, K. S. Ford, M. S. Soloway, J. Urol. 130, 61 (1983).
8. A. A Sandberg, Cancer Genet Cytogenet. 19 (1-2), 163 (1986); E. R Fearon. A. P. Feinberg, S H. Hamilton, B Vogelstein, Nature 318, 377 (1985); Y. C. Tsai et al , Cancer Res. 50, 44 (1990), S -Q. Wu et al., ibid. 51, 3323 (1991); D. Sidransky and E Messing, Urol. Clin. North Am 19, 629 (1992).
9. A. A Sandberg, Cancer Genet Cytogenet. 19 (1-2), 163 (1986); E. R Fearon. A. P. Feinberg, S H. Hamilton, B Vogelstein, Nature 318, 377 (1985); Y. C. Tsai et al , Cancer Res. 50, 44 (1990), S -Q. Wu et al., ibid. 51, 3323 (1991); D. Sidransky and E Messing, Urol. Clin. North Am 19, 629 (1992).
10. A. A Sandberg, Cancer Genet Cytogenet. 19 (1-2), 163 (1986); E. R Fearon. A. P. Feinberg, S H. Hamilton, B Vogelstein, Nature 318, 377 (1985); Y. C. Tsai et al , Cancer Res. 50, 44 (1990), S -Q. Wu et al., ibid. 51, 3323 (1991); D. Sidransky and E Messing, Urol. Clin. North Am 19, 629 (1992).
11. A. A Sandberg, Cancer Genet Cytogenet. 19 (1-2), 163 (1986); E. R Fearon. A. P. Feinberg, S H. Hamilton, B Vogelstein, Nature 318, 377 (1985); Y. C. Tsai et al , Cancer Res. 50, 44 (1990), S -Q. Wu et al., ibid. 51, 3323 (1991); D. Sidransky and E Messing, Urol. Clin. North Am 19, 629 (1992).
12. A. A Sandberg, Cancer Genet Cytogenet. 19 (1-2), 163 (1986); E. R Fearon. A. P. Feinberg, S H. Hamilton, B Vogelstein, Nature 318, 377 (1985); Y. C. Tsai et al , Cancer Res. 50, 44 (1990), S -Q. Wu et al., ibid. 51, 3323 (1991); D. Sidransky and E Messing, Urol. Clin. North Am 19, 629 (1992).
13. D. Sidransky ef al., Science 252, 706 (1991); R H Hruban, P van der Riet, Y. S. Erozan, D Sidransky, N. Engl. J. Med. 330, 1276 (1994).
14. D. Sidransky ef al., Science 252, 706 (1991); R H Hruban, P van der Riet, Y. S. Erozan, D Sidransky, N. Engl. J. Med. 330, 1276 (1994).
15. D Sidransky et al., Science 256, 102 (1992), L Mao, R H Hruban, J. O Boyle, M Tockman, D Sidransky, Cancer Res. 54, 1634 (1994)
16. D Sidransky et al., Science 256, 102 (1992), L Mao, R H Hruban, J. O Boyle, M Tockman, D Sidransky, Cancer Res. 54, 1634 (1994)
17. L. Mao et al , Proc. Natl. Acad Sci U S.A. 91, 9871 (1994).
18. 32P]-adenosine triphosphate (New England Nuclear) Microsatellite loci and primer sequences are available from the authors on request DNA was subjected to 30 to 35 cycles of amplification in a Hybaid (Middlesex, UK) Omnigene TR3 SM2 Thermocycler as follows. 95°C for 30 s, 52° to 60°C for 1 min, and 72°C for 1 min, with a final extension step of 72°C for 5 min PCR products were separated by electrophoresis in denaturing 8 M urea-polyacrylamide-formamide gels, which were then subjected to autoradiography (8).
19. We tabulated the total alterations for each marker tested in all tumors and then grouped, in descending order, the markers most susceptible to alterations that would empirically detect the greatest number of primary tumors Thus, the 10 most susceptible markers empirically identified at least one alteration in 26 of 50 tumors (52%), 11 identified 56% of tumors, 12 identified 60%, 13 identified 62%, and so forth Some markers identified alterations only in tumors previously identified by another marker, and 20% of tumors did not demonstrate a single alteration with any marker tested.
20. P Cairns et al., Nature Genet. 11, 210 (1995)
21. 3 of urine was obtained and concentrated by centrifugation on cytospin glass slides or Millipore filters (Burlington, MA) Cells were stained by Papanicolaou stain and visualized under microscopy Samples were initially screened by a cytotechnologist and reviewed by a cytopathologist. Standard morphologic criteria were used to establish the presence of neoplastic cells.
22. L L Wheeless et al., Cytometry 17, 319 (1994); L E. Moore, N Titenko-Holland, M. T. Smith, Environ Mol. Mutagen. 22(3), 130 (1993).
23. L L Wheeless et al., Cytometry 17, 319 (1994); L E. Moore, N Titenko-Holland, M. T. Smith, Environ Mol. Mutagen. 22(3), 130 (1993).
24. D. Sidransky et al., N. Engl J. Med. 326, 737 (1992).
25. G T. Williams, Cell 65, 1097 (1991); D. E. Fisher, ibid. 78, 539 (1994)
26. G T. Williams, Cell 65, 1097 (1991); D. E. Fisher, ibid. 78, 539 (1994)
27. E Ruoslahti and J. C Reed, ibid. 77, 477 (1994).
28. M.A Knowlese et al., Cancer Res. 54, 531 (1994), W Y-H. Chang, P Cairns, M. P. Schoenberg, T. J Polasick, D. Sidransky, ibid. 55, 3246 (1995 ), M. P. Rosin, P. Cairns, J. I. Epstein, M. P. Schoenberg, D. Sidransky, ibid., p. 5213.
29. M.A Knowlese et al., Cancer Res. 54, 531 (1994), W Y-H. Chang, P Cairns, M. P. Schoenberg, T. J Polasick, D. Sidransky, ibid. 55, 3246 (1995 ), M. P. Rosin, P. Cairns, J. I. Epstein, M. P. Schoenberg, D. Sidransky, ibid., p. 5213.
30. M.A Knowlese et al., Cancer Res. 54, 531 (1994), W Y-H. Chang, P Cairns, M. P. Schoenberg, T. J Polasick, D. Sidransky, ibid. 55, 3246 (1995 ), M. P. Rosin, P. Cairns, J. I. Epstein, M. P. Schoenberg, D. Sidransky, ibid., p. 5213.
31. E Fearon and B. Vogelstein, Cell 61, 759 (1990).
32. H. M. Wenz, Nucleic Acids Res. 22, 4002 (1994).
33. O H. Beahrs, D E. Henson, R. V. P. Hutter, M. H Myers, Eds., Manual for Staging of Cancer (Lippincott, Philadelphia, ed. 3, 1988), p 27.
34. Oncor Inc. (Gaithersburg, MD) provided research funding for this study Under an agreement between Oncor and Johns Hopkins University, D.S. is entitled to a share of sales royalty received by the university from Oncor. Under that agreement, the university and D.S. also have received Oncor stock, which, under university policy, cannot be traded until 2 years after the first commercial sales of the products related to this research. D.S. also serves as a member of the Scientific Advisory Board of OncorMed Inc., an Oncor subsidiary, which is commercializing some of Oncor's technology. The terms of this arrangement have been reviewed and approved by the university in accordance with its conflict-of-interest policies